Intensity Therapeutics, Inc. Common stock (INTS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.11 (+5.93%), Market cap $0.01B, 52-week low–high $0.22 ~ $7.95.
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Financial statements, price targets, institutional (13F) holdings and related news for Intensity Therapeutics, Inc. Common stock are updated in real time on BlackAll Trade.
Intensity Therapeutics, Inc. Common stock trades at $4.11 (+5.93%). Real-time quotes and charts are available on BlackAll Trade.
Intensity Therapeutics, Inc. Common stock has a market cap of about $0.01B.
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United Sta